



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Indatuximab ravtansine

Cat. No.:	HY-141607
CAS No.:	1238517-16-2
Target:	Bacterial; Antibody-Drug Conjugates (ADCs)
Pathway:	Anti-infection; Antibody-drug Conjugate/ADC Related
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities ^[1] .	
In Vitro	Indatuximab ravtansine (1 pM-100 nM; 5 days) shows cytotoxic effects in RPMI 8226, MOLP-8 and U266 cell lines (significant CD138 expression), with IC ₅₀ values of 200 pM, 40 pM, and 20 pM for RPMI 8226, MOLP-8, and U266 cells, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Cell Viability Assay ^[1]	
	Cell Line:	RPMI 8226, MOLP-8 and U266 cell lines
	Concentration:	1 pM-100 nM
	Incubation Time:	5 days
	Result:	Showed cytotoxic effects in RPMI 8226, MOLP-8 and U266 cell lines.
In Vivo	Indatuximab ravtansine (5.3-21.2 mg/kg; i.v.; once) inhibits multiple myeloma tumour growth in vivo and improves host survival ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	SCID mice inoculated with MOLP-8 multiple myeloma xenografts ^[1]
	Dosage:	5.3 mg/kg, 10.6 mg/kg or 21.2 mg/kg
	Administration:	i.v.; once
	Result:	Inhibited multiple myeloma tumour growth in vivo and improved host survival.

REFERENCES

[1]. Kurt Schönfeld, et al. Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies. J Hematol Oncol. 2017 Jan 11;10(1):13.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA